<DOC>
	<DOCNO>NCT03054207</DOCNO>
	<brief_summary>HIV patient particular risk develop cardiovascular disease ( CVD ) exhibit multiple risk factor nature pathology . In addition , long term exposition antiretroviral drug associate increase risk CVD . HIV patient thus potentially receive antiplatelet therapy concomitantly antiretroviral treatment . Clopidogrel prasugrel thienopyridine antiplatelet agent indicate prevent recurrence ischemic event coronary artery stenting . These pro-drugs mainly bioactivated cytochrome P450 ( CYP ) 3A 2B6 prasugrel CYP2C19 , CYP3A CYP2B6 clopidogrel . Ritonavir commonly use `` boost '' bioavailability HIV drug inhibition CYP3A4 well CYP2B6 CYP2C9 . This interaction could therefore reduce clopidogrel prasugrel efficacy reduce formation active metabolite . The aim present study assess potential drug-drug interaction clopidogrel/prasugrel ritonavir . Two group 12 male subject constitute ( 12 HIV patient ritonavir boost therapy 12 healthy volunteer ) randomize cross-over clinical trial . All subject also genotyped CYP2C19 . The pharmacokinetics clopidogrel active metabolite prasugrel active metabolite assess . Furthermore , pharmacodynamic response evaluate two gold standard platelet inhibition test , namely VAsodilator-Stimulated Phosphoprotein Assay ( VASP ) VerifyNowÂ® assay . The primary endpoint study compare pharmacodynamic response clopidogrel prasugrel HIV patient healthy volunteer .</brief_summary>
	<brief_title>Impact Antiretroviral Treatment Pharmacokinetics Pharmacodynamics Thienopyridines Healthy Volunteers HIV Patients</brief_title>
	<detailed_description />
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Healthy male &gt; 18 year Understanding French language able give inform consent AntiHIV therapy ritonavir cobicistat ( HIV group ) Stable antiretroviral treatment since least 2 week ( HIV group ) Viremia &lt; 100 copies/ml ( HIV group ) renal failure : calculated creatinine Clearance ( cockcroft ) &lt; 50ml/min hepatic impairment ( ASAT , ALAT , bilirubin , gammaGT 2fold increase ) smoker &gt; 1 pack/day hypersensitivity drug use intake drug particular food ( grapefruit ) affect CYP activity inhibitor ( last 10 day start study 4 halflife last intake ) pathologies drug associate increase bleed risk aspirin , nonsteroidal antiinflammatory drug , steroid serotonin reuptake inhibitor ( last 10 day start study 4 halflife last intake ) bleed familial history antecedent haemorrhagic disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>